Vical News

STOCK MARKETING INC PRESENTS : AGR Tools, Inc., QLT, Inc., SAVVIS, Inc., Vertro, Inc., Vical Inc., China BAK Battery, Inc.

Vical Incorporated announced today the issuance of U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 . HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes.

Dallas, TX - Cell Therapeutics, Inc. surged 8.57% to $1.14 on 47.57 million shares.

Vical Incorporated announced today that the company is addressing an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company's DNA vaccine technology and Vaxfectin adjuvant.

The Emerging Technologies Conference at M.I.T. ended a few days ago with a focus on developing universal flu vaccines.

Shares of Ciena Corp. headed higher as Nortel Networks Corp.'s announcement Friday of a delay in the auction of its optical unit was seen as positive for the company.

Vical Incorporated today is presenting a strong rationale advocating the use of DNA vaccine technology for emerging and/or pandemic infectious diseases.

Isis , Ligand and Vical have been my core biotech holdings since the mid 1990s and I have been steadily adding to these positions each time the market has lost faith.

Good day and welcome ladies and gentleman to the Vical Incorporated financial results conference call.

Vical Incorporated announced today the publication of two articles regarding the company's Vaxfectin adjuvant in a special issue of Vaccine.

Channa Basava has been named chief operating officer for Louisville biotech company Peptides International Inc.

Several small-cap stocks were poised to move on above-average volume during Wednesday's session.

Stock futures swung into the red ahead of the official start of earnings season and threatening to end the market's two- day rally.

Vical Incorporated announced today that the company's TransVax cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

The U.S. Navy has awarded Vical Inc. a contract for $1.25 million to support a Phase 1 clinical trial of the company's vaccine for H1N1 influenza, more commonly known as swine flu.

Stock futures were pointing to a lower opening after the weekly jobless claims number came in higher than expected.

Vical Incorporated announced today that the company's licensee, sanofi-aventis, has confirmed the completion of enrollment in a multinational 500-patient pivotal Phase 3 clinical trial of its angiogenesis therapy based on Vical's non-viral DNA delivery technology.

Stock were slightly higher at the open as traders cheer a decline in weekly jobless claims.

Vical Incorporated announced today that detailed results from a four-month interim analysis in an ongoing Phase 2 trial of the company's TransVax therapeutic cytomegalovirus DNA vaccine were presented yesterday in a late-breaker session at the Interscience Conference on Antimicrobial Agents and Chemotherapy .

Biotechnology company Vical Inc. said Thursday its developing swine flu vaccine prompted "robust" immune responses in 100 percent of animals infected with distinct strains of the virus.